Prime Medicine, Inc. PRME 深 沪
已收盘 04-02 16:00:00 美东时间
3.32
-0.070
-2.06%
华盛通- 最 高3.4501
- 今 开3.23
- 成交量 165.14万股
- 最 低 3.23
- 昨 收 3.39
- 总市值 5.99亿
- 52周最高 6.94
- 市盈率 静 --
- 换手率 0.91%
- 52周最低 1.11
- 委 比 -89.49%
- 总股本 1.81亿
- 历史最高 21.73
- 量 比 0.59
- 振 幅 6.49%
- 历史最低 1.11
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Advanced Cell-based Therapy Booming the Success for Healthcare Sector
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 24, 2026 /PRNewswire/ -- USANewsGroup.com — The FDA has approved more than 40 cell and gene therapy products. The regenerative medicin...
03-24 22:00
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11
Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.
03-13 01:13
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /PRNewswire/ -- Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, pow...
01-03 02:29
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6
LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $6.
2025-12-24 00:13
Prime Medicine Announced New England Journal Of Medicine Publication Of PM359 Clinical Data For Two Patients For Treatment Of Chronic Granulomatous Disease
Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 clinical data with
2025-12-08 06:28
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
Chardan Capital Maintains Buy on Prime Medicine, Lowers Price Target to $9
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $10 to $9.
2025-11-10 20:21
